actitrexx.de bewertung und analyse
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
Meta Tags
| Title | Home |
| Description | Mission & ActiTrexx has developed a cellular therapy with activated regulatory T cells (ATreg) to minimize the high risk of rejection after stem cell |
| Keywords | Treg, cell therapy, GvHD, stem cell transplantation, ATMP, biotechnology, leukemia |
Server Information
| WebSite | |
| Host IP | 217.160.0.137 |
| Location | Germany |
Verwandte Websites
| Site | Rank |
| unimedizin-mainz.de | 82,477 |
| tron-mainz.de | 3,249,928 |
| gpe-mainz.de | 4,549,848 |
| mainzoo.de | 2,653,253 |
| klein-mainz.de | 18,254,687 |
Mehr zu entdecken
actitrexx.de bewertung
|
Euro€1,102
Zuletzt aktualisiert: 2022-07-01 15:16:04
actitrexx.de hat Semrush globalen Rang von 26,746,362. actitrexx.de hat einen geschätzten Wert von € 1,102, basierend auf seinen geschätzten Werbeeinnahmen. actitrexx.de empfängt jeden Tag ungefähr 551 einzelne Besucher. Sein Webserver befindet sich in Germany mit der IP-Adresse 217.160.0.137. Laut SiteAdvisor ist actitrexx.de sicher zu besuchen. |
Verkehr & Wertschätzungen
| Kauf-/Verkaufswert | Euro€1,102 |
| Tägliche Werbeeinnahmen | Euro€29,754 |
| Monatlicher Anzeigenumsatz | Euro€9,918 |
| Jährliche Werbeeinnahmen | Euro€1,102 |
| Tägliche eindeutige Besucher | 551 |
| Hinweis: Alle Traffic- und Einnahmenwerte sind Schätzungen. | |
DNS Records
| Host | Type | TTL | Data |
| actitrexx.de. | A | 598 | IP: 217.160.0.137 |
| actitrexx.de. | AAAA | 598 | IPV6: 2001:8d8:100f:f000::250 |
| actitrexx.de. | NS | 86400 | NS Record: ns.udag.de. |
| actitrexx.de. | NS | 86400 | NS Record: ns.udag.net. |
| actitrexx.de. | NS | 86400 | NS Record: ns.udag.org. |
| actitrexx.de. | MX | 3600 | MX Record: 20 mx01.udag.de. |
| actitrexx.de. | MX | 3600 | MX Record: 10 mx00.udag.de. |
| actitrexx.de. | TXT | 3600 | TXT Record: MS=ms37129588 |
HtmlToTextCheckTime:2022-07-01 15:16:04
| Home Team Publications Technology & Patents Jobs Mission & Vision ATreg – For a life without Transplant Rejection Graft-versus-Host-Disease (GvHD) is a common complication of stem cell transplantation that is associated with high morbidity and mortality. Our goal is to prevent the development of GvHD at an early stage with the cellular therapy ATreg and thus to provide a curative therapy with few side effects for patients with blood stem cell transplantation for the first time. ATreg is a safe and efficient treatment option for transplanted patients providing substantial improvement of survival rate and quality of life. ATreg addresses a high unmet medical need and has the potential to solve the current risks and limitations inherent with stem cell transplantation. About GvHD: GvHD is a life-threatening side effect of stem cell transplantation. Donor lymphocytes react against tissue antigens in the recipient and cause severe organ and tissue damage, that often takes a chronic course. |
HTTP Headers
HTTP/1.1 302 Moved Temporarily Server: nginx Date: Wed, 27 Oct 2021 13:21:50 GMT Content-Type: text/html Content-Length: 138 Connection: keep-alive Keep-Alive: timeout=15 Location: https://actitrexx.de/ Expires: Wed, 27 Oct 2021 13:41:50 GMT Cache-Control: max-age=1200 HTTP/2 200 content-type: text/html content-length: 11618 date: Wed, 27 Oct 2021 13:21:51 GMT server: Apache last-modified: Mon, 04 Oct 2021 08:33:52 GMT etag: "2d62-5cd82c5e1b82e" accept-ranges: bytes |